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Cytological analysis performed following staging laparoscopy forrecent years as improvements in vector design have resulted in aug-
mented selectivity for speciﬁc cancer types as well as more potent
anti-cancer effects. There is probably no greater evidence of such
progress as the recent Food and Drug Administration (FDA) approval
of talimogene laherparepvec (T-VEC) for the treatment of melanoma
following the published results of the OPTiM study (Andtbacka et al.,
2015). As the ﬁrst FDA-approved oncolytic virotherapy in the United
States, it will hopefully serve as a stepping-stone for the development
and approval of additional viral-based therapies.
Another important component to the evolution of oncolytic
virotherapy has been its use in non-invasive bioimaging. With increas-
ing numbers of vectors entering into trials, the ability to effectively
monitor the pharmacokinetics and pharmacodynamics of infection
will be critical. Some groups have employed transgenes such as an en-
hanced green ﬂuorescent protein (eGFP) to analyze ﬂuorescence from
their vectors (Adusumilli et al., 2011). Other avenues of investigation
have looked into reporter genes encodingmembrane transport proteins
such as the sodium iodide symporter (NIS) (Miller and Russell, 2016).
One application of these molecular imaging techniques is to use the
information that they can provide to augment diagnostic techniques in
difﬁcult clinical situations. For example, pancreatic adenocarcinoma has
one of the poorest survivals for all types of malignancies. Even with
modern chemotherapeutics and clinical care, the overall ﬁve year sur-
vival rate is only on the order of 6%. For patients with localized disease,
surgical resection remains a cornerstone of therapy.
A critical component to care of these patients is ensuring that they
are appropriate candidates for surgery, and that they do not have met-
astatic disease. Staging laparoscopy has the potential for identifying
metastatic liver or peritoneal disease in patients who were otherwise
thought to have only localized disease on cross sectional imaging
(Pisters et al., 2001). This practice has not been universally adopted
and there is no standard criteria for selecting the appropriate patients
(De Rosa et al., 2016). However, some authors have found a correlationDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2016.03.043.
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ease at the time of laparoscopy, and thereby suggest that these patients
may be better candidates to undergo such a procedure (Karachristos
et al., 2005).
patient with pancreatic adenocarcinoma is highly speciﬁc, but lacking
in sensitivity. This study by Kelly et al. has sought to improve upon
conventional cytology by employing amodiﬁed herpes virus expressing
the eGFP gene to better identify tumor cells in peritoneal washings
(Kelly et al., 2016).
The NV1066 virus used in the study is an attenuated, replication-
competent oncolytic herpes simplex virus type 1 (HSV-1). Additionally,
the eGFP transgenewas inserted into the virus genome and is under the
control of the cytomegalovirus promoter. Previously, this vector has
been demonstrated to have the ability to detect as few as one cancer
cell in a backgroundof onemillion normal cells (Adusumilli et al., 2011).
Eighty-two patients with proven pancreatic adenocarcinoma were
enrolled in the study. Peritonealwashingwere obtainedduringdiagnostic
laparoscopy and then analyzed by conventional cytology and HSV-
mediated ﬂuorescence detection. In the cytology arm, the sensitivities
for detecting any metastatic disease and for the detection of peritoneal
metastases were 44% and 89% respectively. In contrast, the viral-
mediated detection arm had sensitivities of 94% and 100% respectively.
For those patientswith negative conventional cytologywhowent on
to curative-intent surgery, there was a statistically signiﬁcant (p =
0.01) decrease in recurrence free survival for those patients who were
eGFP positive (6.5 months) compared to eGFP negative patients
(12.2 months).
As the authors have explained,many patientswith pancreatic cancer
undergo staging laparoscopy and peritoneal washings, only to have a
false-negative result upon cytological analysis. In this manuscript, they
have clearly demonstrated that their modiﬁed herpes virus was
effective at infecting and replicating within pancreatic adenocarcinoma
cells from many different patients. This application of oncolytic virus-
based imaging outperforms conventional cytology approaches as
evidence by the markedly increased diagnostic sensitivity. This type of
information can and will be helpful in guiding clinical decision making
for patients with pancreatic adenocarcinoma.
Given the results of this study, it is clear that this herpes simplex
oncolytic virus deserves further testing in larger trials so that it can
continue to move towards FDA approval for clinical use. The potentialtp://creativecommons.org/licenses/by/4.0/).
16 C.J. LaRocca, J. Davydova / EBioMedicine 7 (2016) 15–16applications of this vector extend beyond pancreatic cancer, and we
would also anticipate that the authorswill be pursuing additional studies
analyzing peritoneal washings for other malignancies, such as gastric
cancer.
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